Impact of tumor necrosis factor inhibitors and methotrexate on diabetes mellitus among patients with inflammatory arthritis
Abstract Background To determine whether initiation of a tumor necrosis factor inhibitor (TNFi) or methotrexate improves hemoglobin A1c in patients with psoriatic arthritis (PsA), rheumatoid arthritis (RA), or ankylosing spondylitis (AS) who also have diabetes mellitus (DM). Methods A retrospective...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-09-01
|
Series: | BMC Rheumatology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s41927-020-00138-3 |
id |
doaj-901d1a883d754190b28d81d516299ed7 |
---|---|
record_format |
Article |
spelling |
doaj-901d1a883d754190b28d81d516299ed72020-11-25T02:43:33ZengBMCBMC Rheumatology2520-10262020-09-014111010.1186/s41927-020-00138-3Impact of tumor necrosis factor inhibitors and methotrexate on diabetes mellitus among patients with inflammatory arthritisSanthi Mantravadi0Michael George1Colleen Brensinger2Min Du3Joshua F. Baker4Alexis Ogdie5Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson UniversityDepartment of Medicine, Division of Rheumatology, Perelman School of Medicine, University of PennsylvaniaDepartment of Biostatistics, Epidemiology, and Informatics, Division of Rheumatology, Perelman School of Medicine, University of PennsylvaniaDepartment of Biostatistics, Epidemiology, and Informatics, Division of Rheumatology, Perelman School of Medicine, University of PennsylvaniaDepartment of Medicine, Division of Rheumatology, Perelman School of Medicine, University of PennsylvaniaDepartment of Medicine, Division of Rheumatology, Perelman School of Medicine, University of PennsylvaniaAbstract Background To determine whether initiation of a tumor necrosis factor inhibitor (TNFi) or methotrexate improves hemoglobin A1c in patients with psoriatic arthritis (PsA), rheumatoid arthritis (RA), or ankylosing spondylitis (AS) who also have diabetes mellitus (DM). Methods A retrospective cohort study was conducted in Optum’s de-identified Clinformatics® Data Mart Database, an administrative claims database, using data from 2000 to 2014. Patients with PsA, RA, or AS, with DM (defined by ICD-9-CM codes) and/or HbA1c ≥7%, who newly initiated either a TNFi, MTX, or metformin (positive control) were identified. The change in HbA1c after drug initiation was calculated. Statistical differences in the change in HbA1c between drugs were assessed using the Wilcoxon rank sum test and linear regression models adjusting for potential confounders. Results Among 10,389 drug initiations in 9541 patients with PsA, RA, or AS, and available HbA1c values, HbA1c was ≥7 at baseline in 254 (35%) TNFi initiations, 361(37%) MTX initiations, and 2144 (50%) metformin initiations. Median HbA1c change was − 0.35 (IQR -1.10, 0.30) after TNFi initiation, − 0.40 (IQR -1.20, 0.30) after MTX initiation, and − 0.80 (IQR -1.60, − 0.10) after metformin initiation. In adjusted analyses, TNFi initiators had less of a decrease in HbA1c compared to MTX initiators (β 0.22, 95% CI: 0.004, 0.43), p = 0.046. Metformin initiators had a significantly greater decrease in HbA1c than MTX, β − 0.38 (95% CI: − 0.52, − 0.23), p < 0.001. Glucocorticoid use was not accounted for in the models. Conclusion HbA1c decreased with TNFi initiation or MTX initiation. Reductions in HbA1c after initiation of a TNFi or MTX are about half (~ 0.4 units) the decrease observed after initiation of metformin.http://link.springer.com/article/10.1186/s41927-020-00138-3Psoriatic arthritisRheumatoid arthritisAnkylosing spondylitisDiabetes mellitusOutcomesEpidemiology |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Santhi Mantravadi Michael George Colleen Brensinger Min Du Joshua F. Baker Alexis Ogdie |
spellingShingle |
Santhi Mantravadi Michael George Colleen Brensinger Min Du Joshua F. Baker Alexis Ogdie Impact of tumor necrosis factor inhibitors and methotrexate on diabetes mellitus among patients with inflammatory arthritis BMC Rheumatology Psoriatic arthritis Rheumatoid arthritis Ankylosing spondylitis Diabetes mellitus Outcomes Epidemiology |
author_facet |
Santhi Mantravadi Michael George Colleen Brensinger Min Du Joshua F. Baker Alexis Ogdie |
author_sort |
Santhi Mantravadi |
title |
Impact of tumor necrosis factor inhibitors and methotrexate on diabetes mellitus among patients with inflammatory arthritis |
title_short |
Impact of tumor necrosis factor inhibitors and methotrexate on diabetes mellitus among patients with inflammatory arthritis |
title_full |
Impact of tumor necrosis factor inhibitors and methotrexate on diabetes mellitus among patients with inflammatory arthritis |
title_fullStr |
Impact of tumor necrosis factor inhibitors and methotrexate on diabetes mellitus among patients with inflammatory arthritis |
title_full_unstemmed |
Impact of tumor necrosis factor inhibitors and methotrexate on diabetes mellitus among patients with inflammatory arthritis |
title_sort |
impact of tumor necrosis factor inhibitors and methotrexate on diabetes mellitus among patients with inflammatory arthritis |
publisher |
BMC |
series |
BMC Rheumatology |
issn |
2520-1026 |
publishDate |
2020-09-01 |
description |
Abstract Background To determine whether initiation of a tumor necrosis factor inhibitor (TNFi) or methotrexate improves hemoglobin A1c in patients with psoriatic arthritis (PsA), rheumatoid arthritis (RA), or ankylosing spondylitis (AS) who also have diabetes mellitus (DM). Methods A retrospective cohort study was conducted in Optum’s de-identified Clinformatics® Data Mart Database, an administrative claims database, using data from 2000 to 2014. Patients with PsA, RA, or AS, with DM (defined by ICD-9-CM codes) and/or HbA1c ≥7%, who newly initiated either a TNFi, MTX, or metformin (positive control) were identified. The change in HbA1c after drug initiation was calculated. Statistical differences in the change in HbA1c between drugs were assessed using the Wilcoxon rank sum test and linear regression models adjusting for potential confounders. Results Among 10,389 drug initiations in 9541 patients with PsA, RA, or AS, and available HbA1c values, HbA1c was ≥7 at baseline in 254 (35%) TNFi initiations, 361(37%) MTX initiations, and 2144 (50%) metformin initiations. Median HbA1c change was − 0.35 (IQR -1.10, 0.30) after TNFi initiation, − 0.40 (IQR -1.20, 0.30) after MTX initiation, and − 0.80 (IQR -1.60, − 0.10) after metformin initiation. In adjusted analyses, TNFi initiators had less of a decrease in HbA1c compared to MTX initiators (β 0.22, 95% CI: 0.004, 0.43), p = 0.046. Metformin initiators had a significantly greater decrease in HbA1c than MTX, β − 0.38 (95% CI: − 0.52, − 0.23), p < 0.001. Glucocorticoid use was not accounted for in the models. Conclusion HbA1c decreased with TNFi initiation or MTX initiation. Reductions in HbA1c after initiation of a TNFi or MTX are about half (~ 0.4 units) the decrease observed after initiation of metformin. |
topic |
Psoriatic arthritis Rheumatoid arthritis Ankylosing spondylitis Diabetes mellitus Outcomes Epidemiology |
url |
http://link.springer.com/article/10.1186/s41927-020-00138-3 |
work_keys_str_mv |
AT santhimantravadi impactoftumornecrosisfactorinhibitorsandmethotrexateondiabetesmellitusamongpatientswithinflammatoryarthritis AT michaelgeorge impactoftumornecrosisfactorinhibitorsandmethotrexateondiabetesmellitusamongpatientswithinflammatoryarthritis AT colleenbrensinger impactoftumornecrosisfactorinhibitorsandmethotrexateondiabetesmellitusamongpatientswithinflammatoryarthritis AT mindu impactoftumornecrosisfactorinhibitorsandmethotrexateondiabetesmellitusamongpatientswithinflammatoryarthritis AT joshuafbaker impactoftumornecrosisfactorinhibitorsandmethotrexateondiabetesmellitusamongpatientswithinflammatoryarthritis AT alexisogdie impactoftumornecrosisfactorinhibitorsandmethotrexateondiabetesmellitusamongpatientswithinflammatoryarthritis |
_version_ |
1724768572984524800 |